Factor XII CRISPR/Cas9 KO Plasmid (h): sc-409611
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Factor XII CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Factor XII genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Factor XII Antibody (C-8): sc-376770
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Factor XII CRISPR/Cas9 KO Plasmid (h) | sc-409611 | 20 µg | $397.00 |
Overview
F12 encodes coagulation Factor XII, a serine protease zymogen that initiates the contact activation pathway upon exposure to negatively charged surfaces, triggering FXI activation and propagating intrinsic coagulation. Activated Factor XII (FXIIa) also couples coagulation to the kallikrein–kinin system by promoting prekallikrein activation and bradykinin generation, linking hemostasis to inflammation and vascular permeability. Through these cascades, F12 contributes to thromboinflammatory signaling and intersects with complement and innate immune pathways. Dysregulated FXII activity is studied in contexts such as thrombosis biology, angioedema mechanisms, and inflammatory vascular disorders, making F12 a useful node for pathway dissection in blood and endothelial models.
Factor XII CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the F12 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the F12 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the F12 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Factor XII protein expression.
This CRISPR knockout system enables efficient generation of F12-deficient cell models for investigation of Factor XII signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting F12 exon(s) critical for Factor XII function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple F12 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Factor XII CRISPR/Cas9 KO Plasmid (h) and Factor XII CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the F12 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Factor XII HDR Plasmid (h) and Factor XII HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by F12 homology arms to support homology-directed repair at defined F12 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.